Compositions comprising a progranulin domain for the prevention and treatment of neurodegenerative diseases

Abstract

This invention provides a compound comprising a granulin precursor domain, a TfR1 binding domain, and, depending on the case, an albumin binding domain, which, when administered to a patient (such as a human), can: (1) regulate tau in the patient; (2) cause a decrease in tau in patients who previously had elevated tau; (3) prevent tau tangles in patients without elevated tau or in patients with elevated tau; and / or (4) prevent the accumulation of tau in patients without elevated tau and / or prevent an increase in tau levels in the patient. Administration of this compound can be used to treat and prevent neurodegenerative diseases. A compound comprising a progranulin domain, a TfR1 binding domain, and optionally an albumin binding domain when administered to a patient, such as a human, can: (1) modulate tau in the patient, (2) lead to the reduction of tau in a patient previously having elevated tau, (3) lead to the prevention of tau tangles in a patient without elevated tau or in a patient having elevated tau, and / or (4) prevent the accumulation of tau in a patient without elevated tau and / or prevent a patient's tau levels from becoming elevated. Treatment and prevention of a neurodegenerative disease through the administration of the compound.

Images